The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Let's just hope we all do well out of this whether you are a whale or a shrimp. More importantly we are ticking off the days. Who will be the golden ticket winner.
26th - Charles175, B311apad
29th - dhub, Idiot
30th - Moorscloud, NCTrade (Yes I remember, but cant remember who maintained it)
31st - PK1
1st - Hedge
2nd - Tillywhiz
5th - Blastoid7
6th - Brendy23
7th - Chris0123, ribbit2
8th - Saint68
9th - MrJinx
10th - Cyrox
A few shorts closing have just been posted too.
23-Jan-24 16:33:33 3.02 135,000 Unknown* 2.80 3.00 4,077 O
23-Jan-24 15:50:54 3.05 200,000 Unknown* 2.80 3.00 6,100 O
23-Jan-24 16:33:33 3.02 -135,000 Unknown* 2.80 3.00 -4,077 O
23-Jan-24 15:50:54 3.05 -200,000 Unknown* 2.80 3.00 -6,100
Some historical coverage on HEMO's CAR-T proposition and wider CAR-T info.
https://www.sciencedirect.com/science/article/pii/S0006497121036673
https://journals.lww.com/co-hematology/fulltext/2022/03000/chimeric_antigen_receptor_t_cell_therapy_in_acute.3.aspx
About CAR-T more generally
https://www.pennmedicine.org/news/news-blog/2023/august/carl-june-on-the-boundless-potential-of-car-t-cell-therapy
Always thought it strange when the MMs are happy to buy 3x what they will sell. additionally, you would have thought that they would tweak up the ASK if they were happy to buy more than they would sell. Hey ho, it's a black box of smoke and mirrors that they play with!
HL will take a max 1.1m at 2.85p. Still demonstrates they are happy to take reasonable numbers of shares... we will be going up more then today I suspect. To be honest, as said below, 5% a day gain would be preferred, rotate the shareholders increasing the average they have bought in at before hopefully a leap on IND.
Tick tock. Moving up nicely! The question is at what price is the IND approval baked in. Everyone is hoping for a leap in SP on approval but if we get up to 4p say... is that then factored in so only a relatively small movement? Nice problem to have in the short term.
Hoping Prevail are diligently working away in the background lining up patients to test CAR-T on the previso of IND approval and keep things seamlessly moving forward. I doubt we will have any shortage of candidates given the terminal nature of AML, a new treatment is likely to be attractive to a patient. AS JHFH has said, it is a slightly unusual position that there isnt necessarily the requirement for dosage/safety is less relevant in Phase I given the terminal nature of the patients.
9 days to my guess :-)
It's not pump/dump if you have been here holding for 5 years like all the LTH. This is the moment that we have been longing for... finally close to IND on the lead CAR-T product. The appetiser to CBR over the coming years.
All ticking up nice. Just need 60p for retirement... £690m market cap. Almost there :-)
In all seriousness, whilst the IND approval is binary, it is a derisked submission i.e. the FDA indicated what the issue was on last submission. HEMO has undertaken its repeat tests after addressing the challenge. One would think that this leaves HEMO in a strong position for IND approval.
CBR lurking in the background as a panacea, albeit very early days.
The prospects are fantastic and at 60p retirement target... only a third of JHFH long-term target. I'll be on the beach well before you :-)
I know what you mean Mickey. No shortage of good news and the SP is still at 2p. Any potential momentum gets squashed by a round of funding. I'm really hoping the IND approval will act as a kick start. HEMO has definitely tested my patience over the years!
Excellent news, quicker submission than I expected. Equally I dont think it will take the 30 days given its an amendment rather than a new submission. Agree with Dhub that it could be 2-3 weeks.
Prevail get on with sourcing patients please.
Happy NY everyone. Should be an exciting 12 months, albeit I said the same in Jan 23! Should be in much better shape now... just need that IND submitting (given RNS last time, I assume it hasnt this time) and a swift IND approval, and we are off to the races. Fingers crossed for the patients and us that CAR-T works!
CBR still the wild card but as JHFH says, it is nascent and will require a lot of funding. That said, if it does half of what DVS thinks then it would be a gamechanger. Not sure I have the patience to see CBR through, but looking for positive results on CAR-T.